¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç° ¹× ¼­ºñ½ºº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Cell-based Assays Market Size, Share & Trends Analysis Report By Products & Services (Reagents, Assay Kits), By Application (Basic Research, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1552896
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,401,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,813,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,637,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, Àü ¼¼°è ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 338¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀÔ´Ï´Ù. ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ´Â ÀǾàǰ °³¹ßÀ» °¡¼ÓÈ­ÇÏ°í °­È­ÇÏ´Â µ¥ È¿°úÀûÀÎ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ¾÷°èÀÇ ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ Ä¡·áÁ¦¸¦ ¾ÈÁ¤ÀûÀ¸·Î °ø±ÞÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¿¹¸¦ µé¾î, ÀÌ·¯ÇÑ ºÐ¼®Àº Ä¡·á ÀÛ¿ë ¸ÞÄ¿´ÏÁò, ¾àÈ¿, ¾ÈÀü¼º ¹× µ¶¼º Å×½ºÆ®¿¡ ´ëÇÑ ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÏ´Â ¸®µå Èĺ¸¹°ÁúÀÇ ¼±Á¤¿¡ »ç¿ëµË´Ï´Ù. ÀǾàǰ °³¹ß °úÁ¤¿¡¼­ ÀÌ·¯ÇÑ ºÐ¼®ÀÌ ±¤¹üÀ§ÇÏ°Ô Àû¿ëµÊ¿¡ µû¶ó ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®Àº CRISPR-Cas9¿Í °°Àº ÀϺΠ±â¼úÀ» »ç¿ëÇÏ¿© À¯ÀüüÀÇ Á¤È®ÇÑ À§Ä¡ ¹× ¼¼Æ÷¹è¾ç¿¡¼­ ƯÁ¤ ¸¶Ä¿ÀÇ µ¹¿¬º¯ÀÌ, ³ìÀÎ, ³ì¾Æ¿ôÀ» ½±°Ô ÇØ°áÇÒ ¼ö ÀÖ¾î ÀǾàǰ °³¹ß ÇÁ·Î¼¼½º¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

¿¹¸¦ µé¾î, ¼¿ÇÁ·ÎÁ¨ÀÇ Àΰ£ ÃéÀå¾Ï ¼¼Æ÷ÁÖ Æ¯¼º ¾î¼¼ÀÌ Å°Æ®´Â Áٱ⼼Æ÷ÀÇ ºÐÈ­ »óŸ¦ °áÁ¤Çϱâ À§ÇØ ¼¼Æ÷ ³» ´Ü¹éÁú ³óµµ¸¦ ÃøÁ¤ÇÏ´Â ¼¼Æ÷ ±â¹Ý ELISA ŰƮ·Î, ¼¼Æ÷ ¿ëÇØ¹°À» ÁغñÇÒ Çʿ䰡 ¾ø¾î ½Å¾à°³¹ß¿¡ Æø³Ð°Ô Àû¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. ÇÑÆí, ÁÖ¿ä ±â¾÷µéÀº ÆÄÀÌÇÁ¶óÀÎ, Æ÷Æ®Æú¸®¿À, Á¦Ç° ¶óÀξ÷À» È®ÀåÇÏ°í ½ÃÀå ħÅõ¸¦ À§ÇØ ´Ù¾çÇÑ ¼ºÀå Àü·«À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù ¹Ì¼Ç¹ÙÀÌ¿À(Mission Bio, Inc.)´Â ÀǾàǰ ºÐ¼® °³¹ß ¼­ºñ½º¸¦ ÅëÇØ °íÇü Á¾¾ç °ËÃâÀ» À§ÇÑ ºÐ¼®¹ýÀ» Ãâ½ÃÇÏ¿© °íÇü Á¾¾ç Ư¼º Æò°¡¿¡ ¼Ò¿äµÇ´Â ½Ã°£°ú ºñ¿ëÀ» Àý°¨ÇÔÀ¸·Î½á ¾Ï Ä¡·áÁ¦ °³¹ß ÇÁ·Î¼¼½º¸¦ °¡¼ÓÈ­ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, 2022³â 4¿ù Æ÷¹ÙÀÌ¿À»çÀ̾𽺴 ¹Ì±¹¾Ï¿¬±¸Çùȸ¿¡ ÈļºÀ¯ÀüÇпë Chromatrap Ĩ ŰƮ¸¦ HTS(High Throughput Screening) ÇÁ·Î¼¼½º, ¼¼Æ÷ Áõ½Ä ¹× ¼¼Æ÷ Áõ½ÄÀ» À§ÇÑ »õ·Î¿î ºÐ¼®¹ý ¹× »õ·Ó°Ô ¼³°èµÈ ¼¼Æ÷¹è¾ç ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ®¿Í ÇÔ²² Àü½ÃÇß½À´Ï´Ù. ¸¹Àº ¿¬±¸ÀÚ¿Í ÀÓ»óÀǵéÀº ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ, À¯Àü¼º Áúȯ µî Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â Áúº´¿¡ È¿°úÀûÀ¸·Î ´ëóÇϱâ À§ÇØ Áø´Ü¿¡ À¯¿ëÇÏ°í »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇÒ ¼ö ÀÖ´Â »õ·Î¿î ¼¼Æ÷ ±â¹Ý ¾î¼¼À̹ýÀÌ Àý½ÇÈ÷ ¿ä±¸µÇ°í ÀÖ´Ù°í º¸°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹ÍÀº ¿¬±¸ Ȱµ¿ÀÇ Áö¼Ó°ú ¼öÇàµÇ´Â ºÐ¼®ÀÇ Á¾·ù ¸ðµÎ¿¡ Å« Ÿ°ÝÀ» ÀÔÇû½À´Ï´Ù.

¹Ì±¹ ³»¿¡¼­´Â ¸ðµç Á¾·ùÀÇ ¼¼Æ÷ ±â¹Ý ¾î¼¼À̸¦ Æ÷ÇÔÇÑ ¿¬±¸ Ȱµ¿ÀÇ Àç°³¸¦ º¸ÀåÇϱâ À§ÇÑ ³ë·ÂÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®Àº COVID-19 °¨¿°À» ŽÁöÇÏ´Â µ¥¿¡µµ »ç¿ëµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 5¿ù AcroBiosystemÀº ACE2¿Í S1 ´Ü¹éÁú/S1 RBD ´Ü¹éÁú °£ÀÇ °áÇÕÀ» ¿¬±¸ÇÏ´Â À¯¼¼Æ÷ ºÐ¼®¹ýÀ» Ãâ½ÃÇß½À´Ï´Ù. ºÏ¹Ì´Â »ý¸í°øÇÐ ¿¬±¸ÀÇ Áõ°¡, Ä¡·áÁ¦ ¿¬±¸ÀÇ ¼ºÀå, ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç, ³ôÀº ¾Ï À¯º´·ü·Î ÀÎÇØ 2021³â ¼¼°è »ê¾÷À» Áö¹èÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº »ý¸í°úÇÐ ºÐ¾ßÀÇ ¿¬±¸ ¼ö¿ä Áõ°¡¿Í À¯ÀüÀÚ ¼öÁØ¿¡¼­ Áúº´¿¡ ´ëÇÑ ÀÌÇØ Áõ°¡·Î ÀÎÇØ 2022³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå : Á¦Ç° ¹× ¼­ºñ½ºº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå : ¿ëµµº° µ¿Ç⠺м®

Á¦6Àå ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ¼¼Æ÷ ±â¹Ý ¾î¼¼ÀÌ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cell-based Assays Market Growth & Trends:

The global cell-based assays market size is expected to reach USD 33.8 billion by 2030, registering a CAGR of 8.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected to boost the demand. These assays are integral to the drug development process by adopting several technologies, such as CRISPR-Cas9, to allow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.

For instance, Celprogen's human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need to prepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies to expand their pipelines, portfolios, and offerings to penetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services to aid the acceleration of the development process of cancer therapeutics by reducing the time & cost to characterize solid tumors.

Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and to devise new therapeutic regimes to effectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both to the continuance of research activities and the type of assays performed.

There are efforts across the U.S. to ensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay to study the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing to an increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 due to the rising demand for research in life sciences and increased genetic level understanding of diseases.

Cell-based Assays Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Cell-based Assays Market Variables, Trends, & Scope

Chapter 4. Cell-based Assays Market: Products & Services Estimates & Trend Analysis

Chapter 5. Cell-based Assays Market: Application & Trend Analysis

Chapter 6. Cell-based Assays Market: End use Estimates & Trend Analysis

Chapter 7. Cell-based Assays Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â